Table 1.

Demographics, clinical examination at baseline, diagnosis and treatment

ID	Sex	Eye	Age at diagnosis	Associated symptoms	Initial CDVA (LogMAR)	Final CDVA (LogMAR)	Previous known systemic vasculitis	Previous systemic treatment	New diagnosis of systemic vasculitis	Intraveinous corticosteroids pulses (1 g), n	Steroid-sparing first line therapy	Recurrence	Second line therapy
1	M	OD	45	–	0.7	1	Rheumatoid arthritis	Rituximab	No	1	Tapered oral corticosteroids + Rituximab	No	No
2	F	OS	38	–	1	1	Relapsing polychondritis	No	No	3	Tapered oral corticosteroids + methotrexate	Yes	Cyclophosphamide
3	F	OS	74	–	0.4	0.4	No	No	Cryoglobulinemia type 2B	3	Tapered oral corticosteroids + Infliximab	No	No
4	F	OS	56	Scleritis	–	–	Rheumatoid arthritis	Methotrexate, Etanercept	No	3	Tapered oral corticosteroids + Rituximab	No	No
5	F	OD	54	Scleritis, Episcleritis	1	1	No	No	Granulomatosis with polyangiitis	5	Tapered oral corticosteroids	Yes	Cyclophosphamide
6	M	OS	33	–	0.4	0.9	No	No	Connective-tissue disease	4	Tapered oral corticosteroids + methotrexate	Yes	Cyclophosphamide
Mean ± SD					0.7 ± 0.3	0.9 ± 0.3
P value *						0.18

CDVA Corrected distance visual acuity, ID Patient study number, n number, SD standard deviation. *: Wilcoxon paired test